SCHEMBL18158992

SCHEMBL18158992

COC(=O)Cc1cn([C@@H]2O[C@H](CO)[C@H](O)C2OC)c(=O)[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TK2 O00142 10/20 0.53
PYGM P11217 3/20 0.48
DNPH1 O43598 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18573958 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL17082399 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL18870665 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL2027443 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL19614649 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL2027440 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL14853783 1.00 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL30069461 0.91 TK2 (0.53) TK2PYGMDNPH1
SCHEMBL28948294 0.91 TK2 (0.52) TK2PYGMDNPH1
SCHEMBL28948288 0.91 TK2 (0.52) TK2PYGMDNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US disclosed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US disclosed
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 US disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 US disclosed
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TK2 209/4885PYGM 2621/4885DNPH1 1736/4885
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 TK2 151/4885PYGM 1594/4885DNPH1 467/4885
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TK2 209/4885PYGM 2621/4885DNPH1 1736/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TK2 305/4885PYGM 2038/4885DNPH1 2277/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TK2 305/4885PYGM 2038/4885DNPH1 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.